GGB, what you're bringing up fits nicely into the discussion of problems, and non-problems.
In most cases, when a problem is solved, that ends discussion of it. During the many years the company has been in business, many problems have been resolved.
Non-problems can never be fully resolved, because people just keep asking, in spite the fact that they were either never a problem, or were, but were completely resolved. No answer is deemed to be sufficient.
Things like, When was the last time you beat your wife? No answer is forever.
In the case of NWBO many problems have been resolved by working with the regulators to modify how the trial was to be run and evaluated. No company discloses all the changes they make with the concurrence of the regulators, they put out modified guidance, but they don't say all that went into arriving at it.
While the problem has been resolved, in NWBO's case, the resolved problems answer isn't fully accepted, so it just becomes a non-problem.
Things like UCLA's vaccine not being DCVax-L, or the trial being for PFS, just never go away. These non-problems just keep being asked, and answered, but there is always someone who asks it again. Perhaps if the company answered it might be accepted, but the company simply isn't going to tell investors about all the discussions they have with the regulators, etc., and how they're resolved.
Gary
Bullish
Market Data 
Markets 
AI
